Hugel announced on the 3rd that it has obtained an item license for botulinum toxin formulation Letybo from the ANSM on the 27th of last month (local time). Earlier on the 25th, Hugel received an opinion from the HMA to approve Letybo's item license. Upon receipt of the opinion, Hugel entered a national phase to enter 11 European countries, including France, Britain, Germany, Spain, and Italy.

Starting with this approval, Hugel aims to ship Letybo within the first quarter and launch it in major local markets. This is the first case of Korean botulinum toxin formulations entering Europe. Hugel plans to complete its entry into 36 European countries by next year based on its entry into 11 major countries t